Company Overview


Research and Development

The R&D divisions of Sato developing new drugs are consolidated at the Shinagawa R&D Center in Shinagawa, Tokyo. The R&D center contains six buildings, including the New Research Wing and Formulation Research Wing, as well as the Research Planning, Drug Discovery Research, Ethical Pharmaceutical Research, and Formulation Research Departments, which are engaged in cutting-edge research.

Sato develops new drugs using the latest technologies to meet modern requirements

The Shinagawa R&D Center conducts the many research and development activities needed to produce Sato’s ethical pharmaceuticals, OTC drugs, quasi-drugs, cosmetics, and foods for specified health uses. The R&D center pursues research into high value-addition products that are always based on the needs of consumers, and without restriction to existing categories.
 Researchers of all departments participate in projects for each drug discovery theme, and actively engage in research activities such as synthesizing new compounds, biological screening and pharmacodynamic and pharmacokinetic evaluation.
 Sato is conducting research on new and original drugs in the field of ethical pharmaceuticals.
 Sato has four development fields—hyperuricemia therapeutic agents, ophthalmological diseases, infectious diseases, and wound healing—and is engaged in research to deliver the new drugs needed by patients.
 SKX-12 is a unique proprietary drug developed by Sato to treat hyperuricemia, with an action mechanism different from mainstream medications. To gain regulatory approval, Sato is preparing for Phase II clinical study.

Promoting joint research with domestic and international academia

Sato proactively engages in joint research into drug discovery with companies, universities, and research institutes in Japan and overseas.
 We have achieved tangible results in several joint research projects with different universities. First, in a joint research activity with Kyushu University, we have been working on drug discovery targeting lipid metabolism-related coenzymes. Together with Keio University we established a muscle biology/sarcopenia laboratory at the schools Research Park at its Shinanomachi Campus. Here we undertook a joint research project into sarcopenia, the muscular atrophy that comes with aging, and are steadily achieving results.
 We have also begun collaborative research in the field of ophthalmology together with the University of Tokyo. In addition, with several of the faculties of Juntendo University, we have joined in an advanced research course on wound healing, aiming to elucidate the healing mechanisms for wounds and pressure sores, and towards the creation of wound-healing drugs. We will continue to focus on drug discovery research, with a special eye on Japan’s fast-aging society.


More effective and easier to use; unique formulation development and research of ingredients of crude drugs

The formulation design of new pharmaceutical products for improved convenience, safety and effectiveness are major research themes at Sato. For example, we succeeded in creating unique formulations, such as orally-disintegrating tablets that can be taken without water, technology we apply to our own products.
 In crude drug research, we have scientifically certified more than 100 crude drugs. In December 2015, we launched Yunker Kotei Solution Premium, which contains a fortified balance of crude drugs. Leveraging our analysis methods and proprietary research data based on new crude drug ingredients, we will also continue developing new products for the Yunker series, which addresses the fatigue of modern consumers.


Using genetic and protein analytic technology to provide higher-quality scientific evidence

In recent years, as the importance of gene/protein analysis research has increased, Sato has conducted research using molecular biology and gene technology such as screening using cultured cells, part of our focus on obtaining higher-quality scientific evidence. In addition, we are developing new cosmetic products based on scientific evidence, by making use of our original three-dimensional skin culture model, and a screening and evaluation system at the molecular/genetic level.